The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female.
Twenty-five patients complaining of nocturia completed a double-blind cross-over trial using desmopressin (DDAVP) and placebo. All had failed to respond to treatment with antispasmodic agents and evening fluid restriction. The drugs were given as a single intranasal dose on retiring. Nocturnal urinary frequency was reduced from a mean of 3.2 episodes to 2.6 with placebo and 1.9 with DDAVP (0.01 greater than P greater than 0.001). Diurnal urinary symptoms were not significantly affected and side effects were minimal. This drug seems to have a place in the treatment of nocturia, where more conventional therapies have failed.
D000281:Administration, Intranasal; D000328:Adult; D000368:Aged; D001127:Arginine Vasopressin / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004775:Enuresis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged
D001127:Arginine Vasopressin; D003894:Deamino Arginine Vasopressin